CGM

Dexcom Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Pharmaceutical, Health, Diabetes, Medical Devices, Health Technology, Technology, Other Technology, Multimedia, Meal, Senior, DXCM, CGM, ONE, LATAM, Glucose meter, Dexcom, Insulin, Pharmaceutical industry

The system is available today in Spain, Belgium, and Poland and launches next week in the Netherlands.

Key Points: 
  • The system is available today in Spain, Belgium, and Poland and launches next week in the Netherlands.
  • In some countries Dexcom ONE+ replaces the previous generation Dexcom ONE sensor.
  • Dexcom also incorporated feedback from both end users and healthcare professionals when building Dexcom ONE+, ensuring an easy-to-use, highly effective, CGM experience for people treating their Type 1 or Type 2 diabetes with insulin.
  • Dexcom ONE+ is available today in Spain, Belgium and Poland, and will be available in the Netherlands next week.

Automotive Central Gateway Module Market to grow by USD 1.15 billion from 2022 to 2027, Increasing government support to promote EVs to boost the growth - Technavio

Retrieved on: 
Monday, February 5, 2024
Aptiv, Growth, Electronics, Internet of things, Infineon Technologies, CGM, ICE, NXP Semiconductors, ESO, Government, LIN, Continental AG, USD, Climate change, Safety, Challenge, STMicroelectronics, EV, Robert Bosch GmbH, Texas Instruments, Himawari (satellites), Communication, Lear Corporation, Écu, TDK, Risk, Semiconductor industry, EVS, Hitachi

Increasing government support to promote EVs is a key factor driving growth.

Key Points: 
  • Increasing government support to promote EVs is a key factor driving growth.
  • Technavio has segmented the market based on application (passenger cars and commercial vehicles), type (LIN central gateway module, CAN central gateway module, and ethernet central gateway module), and Geography (APAC, North America, Europe, South America, and Middle East and Africa).
  • The automotive central gateway module serves as a critical component in modern automotive electronics, facilitating vehicle connectivity and communication within in-vehicle networks.
  • Overall, the central gateway module enhances vehicle electronics integration and provides automotive connectivity solutions for advanced automotive systems.

Trinity Biotech Announces Q3 2023 Financial Results & Business Update

Retrieved on: 
Wednesday, January 31, 2024
USAID, Interim, Growth, ADS, CFO, Consultant, CGM, HIV, Diabetes, Intellectual property, Glucose meter, Interim management, American depositary receipt, Waveform, Service management, Des Fitzgerald, Acquisition, Units of paper quantity, Base rate, Q4, Pharmaceutical industry

DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) today announced the Company’s results for the quarter ended September 30, 2023.

Key Points: 
  • DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) today announced the Company’s results for the quarter ended September 30, 2023.
  • In our HIV business, shipments of Uni-Gold are expected to be lower than Q3, 2023 due to the typical irregular quarter on quarter ordering patterns in that business.
  • At June 30, 2023 and September 30, 2023, the assets and liabilities attributable to Fitzgerald Industries have been de-recognised from the Consolidated Balance Sheet.
  • Total revenues for Q3, 2023 were $14.7 million which compares to $15.7 million in Q3, 2022, a decrease of 6.5% and which were broken down as follows:

Trinity Biotech Announces Acquisition of the CGM Assets of Waveform Technologies, Inc.

Retrieved on: 
Wednesday, January 31, 2024
Partnership, ADS, CGM, History, HIV, Innovation system, Biomarker, Pain, Glucose meter, Dexcom, Trinity, World Health Organization, Trauma, Bayer, American depositary receipt, Acquisition, Base rate, EST, Health, Security (finance)

DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”) today announced it has entered into a definitive agreement to acquire the biosensor and Continuous Glucose Monitoring (“CGM”) assets of privately held Waveform Technologies, Inc. (“Waveform”) for $12.5 million in cash, 9 million American Depositary Shares (“ADSs”) of the Company and additional contingent consideration.

Key Points: 
  • Waveform will no longer sell the Cascade device and the Company will not sell that device in its current form.
  • The remaining $9.5 million is available for general corporate purposes including for the further development of the CGM and biosensor technologies.
  • Waveform is part of a portfolio company of Perceptive and the 9 million ADS being issued by the Company as partial consideration for the acquisition of the Waveform assets will be issued to Perceptive.
  • The Company will host a conference call on Wednesday, January 31 at 8:30 a.m. EST to discuss its recent Waveform acquisition.

Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India

Retrieved on: 
Wednesday, January 31, 2024
Partnership, Public, CGM, Diabetes, Patient, Glucose meter, Trinity, Physician, Bayer, Waveform, Acquisition, Letter, EST, Type 2 diabetes, Pharmaceutical industry

Both parties intend to negotiate a definitive agreement under the framework set by the Letter of Intent in the coming months.

Key Points: 
  • Both parties intend to negotiate a definitive agreement under the framework set by the Letter of Intent in the coming months.
  • In addition to the proposal to enter the Chinese market, the Letter of Intent includes a framework for the intention to launch a CGM device in India.
  • To date, CGM use in India is not widespread, but has been trending higher recently with increasing awareness about self-care.
  • Trinity Biotech will host a conference call on Wednesday, January 31 at 8:30 a.m. EST to discuss its recent Waveform acquisition.

FPT Industrial engines power the construction of the longest immersed tunnel in the world

Retrieved on: 
Tuesday, January 30, 2024
IVG, ASTRA, FPT, Civil service commission, Congestion, CGM, Agriculture, EXM, Iveco, European Commission, IDV, CO2, FPT Industrial, IVECO

FPT Industrial, the brand of Iveco Group (EXM: IVG) specialised in advanced propulsion technologies, is playing a pivotal role in the construction of the Fehmarnbelt tunnel, an 18-kilometre-long tunnel that will provide the fastest connection between Scandinavia and Central Europe and is set to be the world’s longest immersed tunnel.

Key Points: 
  • FPT Industrial, the brand of Iveco Group (EXM: IVG) specialised in advanced propulsion technologies, is playing a pivotal role in the construction of the Fehmarnbelt tunnel, an 18-kilometre-long tunnel that will provide the fastest connection between Scandinavia and Central Europe and is set to be the world’s longest immersed tunnel.
  • FPT Industrial, through its distributor Bimotor S.p.A., has supplied its state-ot-the-art F36 Stage V engines for power generation to CGM, a leading producer of generation sets.
  • These gensets are currently in operation at the massive Fehmarnbelt construction site, which includes the largest concrete factory in the world.
  • The construction of each element requires a significant amount of reliable, ready-to-use energy, and the project has entrusted this to the CGM gensets powered by FPT Industrial engines.

Americares Joins the CMA CGM Foundation's Containers of Hope Program

Retrieved on: 
Tuesday, January 30, 2024
Partnership, Health, CMA CGM, CGM, Hospital, Atmosphere, Container, Poverty, Survivor, Disaster, Medicine, APL, CMA, Intermodal freight transport

STAMFORD, Conn., Jan. 30, 2024 /PRNewswire/ -- Americares has joined CMA CGM Foundation's Containers of Hope program, which will transport humanitarian aid for the health-focused relief and development organization for one year.

Key Points: 
  • STAMFORD, Conn., Jan. 30, 2024 /PRNewswire/ -- Americares has joined CMA CGM Foundation's Containers of Hope program, which will transport humanitarian aid for the health-focused relief and development organization for one year.
  • The Foundation will mobilize the CMA CGM Group's expert staff members to support Americares international supply chain and work alongside Americares logistics staff to coordinate the donated shipments.
  • Americares first shipment through the Containers of Hope program is on the way to Ghana, where Americares partners with a local organization to support 250 hospitals, clinics and health centers.
  • In addition, Americares has aid shipments headed to the Dominican Republic, Lebanon and Liberia thanks to the Containers of Hope program.

EQS-News: E-prescriptions new standard in Germany: CGM with positive interim assessment

Retrieved on: 
Tuesday, January 30, 2024
CGM, Patient, Infection, Pharmacy, TI, Smartphone, Pharmacist, Prescription, SMS, Physician, Pharmaceutical industry

EQS-News: CompuGroup Medical SE & Co. KGaA

Key Points: 
  • EQS-News: CompuGroup Medical SE & Co. KGaA
    E-prescriptions new standard in Germany: CGM with positive interim assessment
    The issuer is solely responsible for the content of this announcement.
  • E-prescriptions new standard in Germany: CGM with positive interim assessment
    Koblenz.
  • Pharmacies using CGM Lauer software have redeemed more than 4 million e-prescriptions in the last four weeks.
  • This is CGM's positive interim balance since e-prescriptions became the new standard in ambulatory healthcare at the beginning of the year.

A Powerful Alliance: Dexcom G7 Now Connects to Tandem t:slim X2

Retrieved on: 
Monday, January 15, 2024
Wearables, Mobile Technology, Technology, Medical Devices, Diabetes, Clinical Trials, Health Technology, Software, Biotechnology, Health, Data Management, CGM, FIN Atlantic Film Festival, Dexcom, EASD, Associate professor, Partnership, Hypoglycemia, University, Risk, DXCM, Diabetic retinopathy, Insulin, G7, Tandem Diabetes Care, AID, Tandem, University of Nottingham, Medical device

DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in countries across Europe and in South Africa.

Key Points: 
  • DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in countries across Europe and in South Africa.
  • The announcement comes just a month after the system launched in the United States and combines the power and accuracy of Dexcom G7 with the discretion of the Tandem t:slim X2.
  • Additionally, the COMISAIR seven-year follow up demonstrated further substantial reduction in HbA1c when Dexcom CGM is connected to the t:slim X2 insulin pump with Control-IQ technology5.
  • To learn more and to get started with Dexcom G7 and the Tandem t:slim X2 insulin pump, visit Dexcom.co.uk/tandem.

Veri Releases New Metabolic Health Program

Retrieved on: 
Thursday, January 11, 2024
Biomarker, Science, CGM, Glucose, Habit, Health, Harvard University, Medical device

HELSINKI, Jan. 11, 2024 /PRNewswire/ -- Today, Veri announced the release of its new in-app metabolic health program , the most significant update yet.

Key Points: 
  • HELSINKI, Jan. 11, 2024 /PRNewswire/ -- Today, Veri announced the release of its new in-app metabolic health program , the most significant update yet.
  • Built by Veri's health team in coordination with advisors from Stanford, Duke, and Harvard, the new four-stage program gives members a personalized metabolic health coach in their pocket:
    Daily guidance to help members understand their metabolic health, glucose levels, and how to make improvements.
  • "At Veri, we believe that every person holds the power to achieve optimal metabolic health through sustainable lifestyle change," said Dr. Vimal Ramjee, Director of Heath at Veri.
  • "With that in mind, we created The Veri Program, a personalized four-stage experience that puts your glucose data into context with your lifestyle to deliver impactful, evidence-based action steps that improve metabolic health."